Aarti Pharmalabs Limited (AARTIPHARM) - Cash Flow Conversion Efficiency

Latest as of September 2023: 0.022x

Based on the latest financial reports, Aarti Pharmalabs Limited (AARTIPHARM) has a cash flow conversion efficiency ratio of 0.022x as of September 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs362.80 Million ≈ $3.92 Million USD) by net assets (Rs16.58 Billion ≈ $179.25 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Aarti Pharmalabs Limited - Cash Flow Conversion Efficiency Trend (2020–2025)

This chart illustrates how Aarti Pharmalabs Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Aarti Pharmalabs Limited for a breakdown of total debt and financial obligations.

Aarti Pharmalabs Limited Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Aarti Pharmalabs Limited ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
BAE Systems plc
LSE:BA
0.265x
Astra Otoparts Tbk
JK:AUTO
0.045x
Vitesse Energy Inc
NYSE:VTS
0.076x
Yunnan Tourism Co Ltd
SHE:002059
0.042x
Viglacera Corp JSC
VN:VGC
0.209x
Shenzhen Easttop Supply Chain Management Co Ltd
SHE:002889
-0.095x
Lotte Confectionery Co Ltd
KO:280360
0.057x
Orrstown Financial Services Inc
NASDAQ:ORRF
0.039x

Annual Cash Flow Conversion Efficiency for Aarti Pharmalabs Limited (2020–2025)

The table below shows the annual cash flow conversion efficiency of Aarti Pharmalabs Limited from 2020 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Aarti Pharmalabs Limited worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-03-31 Rs19.90 Billion
≈ $215.20 Million
Rs3.32 Billion
≈ $35.86 Million
0.167x +35.32%
2024-03-31 Rs17.57 Billion
≈ $190.02 Million
Rs2.16 Billion
≈ $23.40 Million
0.123x -27.03%
2023-03-31 Rs15.58 Billion
≈ $168.54 Million
Rs2.63 Billion
≈ $28.44 Million
0.169x +635.36%
2022-03-31 Rs13.86 Billion
≈ $149.94 Million
Rs-437.04 Million
≈ $-4.73 Million
-0.032x --
2021-03-31 Rs2.27 Million
≈ $24.52K
Rs0.00
≈ $0.00
0.000x --
2020-03-31 Rs2.31 Million
≈ $25.02K
Rs-186.75K
≈ $-2.02K
-0.081x --

About Aarti Pharmalabs Limited

NSE:AARTIPHARM India Drug Manufacturers - Specialty & Generic
Market Cap
$725.68 Million
Rs67.10 Billion INR
Market Cap Rank
#10661 Global
#510 in India
Share Price
Rs740.25
Change (1 day)
+4.39%
52-Week Range
Rs591.95 - Rs964.90
All Time High
Rs964.90
About

Aarti Pharmalabs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. The company offers active pharmaceutical ingredients for various therapeutic areas, such as cardiovascular, anti-asthmatic, anti-cancer, anti-coagulant, anti-diabetic, arthritis, central nervous sys… Read more